Detalles de la búsqueda
1.
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Lancet Infect Dis
; 24(3): 308-318, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061367
2.
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Vaccine
; 39(23): 3197-3206, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33965258
Resultados
1 -
2
de 2
1
Próxima >
>>